EBS vs SIGA
EBS: Emergent BioSolutions is a biopharmaceutical company providing critical medical countermeasures and life-saving naloxone treatments for global public health threats and emergencies. SIGA: SIGA Technologies is a pharmaceutical company providing critical antiviral countermeasures, primarily TPOXX, to protect against smallpox and other orthopoxvirus threats.
Side-by-side fundamentals
| Metric | EBS | SIGA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $6.29 | $3.15 | |
| Market cap | $323M | $226M | |
| Net margin FY2025, SEC XBRL | +7.1% | +24.6% | SIGA higher |
| Gross margin FY2023, SEC XBRL | +30.3% | n/a | |
| Operating margin FY2025, SEC XBRL | +13.5% | +25.1% | SIGA higher |
| ROE FY2025, SEC XBRL | +10.1% | +11.7% | SIGA higher |
| ROA FY2025, SEC XBRL | +4.0% | +10.6% | SIGA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.70 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -28.8% | -31.8% | EBS higher |
| Revenue CAGR (3y) SEC XBRL | -12.7% | -5.1% | SIGA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 4 | SIGA higher |
| Beta as of 2026-09-03 | 1.52 | 0.69 | |
| 1-year return as of 2026-10-20 close | -36.0% | -62.9% | EBS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.